Today: 7 February 2026
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Ford Stock Soars in 2025 as Wall Street Backs EV Reset, Hybrids and an Amazon-Powered Digital Pivot

Ford Stock Soars in 2025 as Wall Street Backs EV Reset, Hybrids and an Amazon-Powered Digital Pivot

Ford Motor Company (NYSE: F) has quietly become one of 2025’s unlikeliest comeback stories. After years of a sluggish share price, the stock is up roughly one‑third this year, outpacing the broader market, even as its electric‑vehicle unit bleeds billions of dollars. Fresh reports and analyst notes published today, 17 November 2025, show why Wall Street is suddenly “in love” with Ford again — and why the story is more complicated than a simple turnaround. 24/7 Wall St.+1 Key Takeaways A 2025 Rally That Leaves the S&P 500 Behind Ford’s stock has staged a powerful comeback this year. According to
17 November 2025
··
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer’s acquisition of Metsera, Inc. (formerly NASDAQ: MTSR) is now effectively complete, Metsera’s stock has been delisted, major index providers are removing the name, and antitrust scholars are using the failed Novo Nordisk bid as a case study in “attempted monopolization.” Here’s a full rundown of what matters today, 17 November 2025, for anyone following Metsera, MTSR, or the obesity‑drug arms race. 1. Where the Metsera–Pfizer Deal Stands Today Pfizer formally closed its acquisition of Metsera on November 13, 2025, after Metsera shareholders approved a sweetened offer that values the obesity biotech at up to $10 billion.Reuters+1 Key terms of
17 November 2025
·
Opendoor (OPEN) News Today: Warrant Dividend, Short Seller Crackdown and Wall Street Caution — November 17, 2025

Opendoor (OPEN) News Today: Warrant Dividend, Short Seller Crackdown and Wall Street Caution — November 17, 2025

Opendoor Technologies (NASDAQ: OPEN) is back in the spotlight as a controversial warrant dividend aimed at short sellers dominates headlines, even as Morgan Stanley reiterates a Hold rating and quants flag huge hedge fund flows. Here’s everything investors need to know about OPEN on November 17, 2025. Market snapshot: OPEN stock today As of this afternoon on November 17, 2025, Opendoor Technologies Inc. (NASDAQ: OPEN) is trading around $8.03, down roughly 1% on the day after an explosive run that recently sent the stock above $10. Despite today’s mild pullback, OPEN remains: At the center of today’s news cycle: Opendoor’s
17 November 2025
Ondas Holdings (ONDS) Lands $8.2M Airport Drone Defense Deal and Closes $225M Sentrycs Acquisition on November 17, 2025

Ondas Holdings (ONDS) Lands $8.2M Airport Drone Defense Deal and Closes $225M Sentrycs Acquisition on November 17, 2025

Ondas Holdings Inc. (NASDAQ: ONDS), a provider of autonomous drone systems and private wireless networks, packed several major announcements into Monday, November 17, 2025 – including a new multimillion‑dollar European airport contract, the closing of a $225 million acquisition, and fresh bullish analyst signals. Stock Titan Together, the developments underscore how aggressively Ondas is positioning itself at the center of the global counter‑drone and autonomous defense market. Key takeaways for November 17, 2025 As of the latest intraday data on November 17, 2025, ONDS was trading around $7.00 per share, down roughly 2.5% on the day after a sharp run‑up
17 November 2025
··
Light & Wonder (ASX:LNW): ASX‑Only Listing, $1.5bn Buyback Shift and Fresh Fund Moves – 17 November 2025 Update

Light & Wonder (ASX:LNW): ASX‑Only Listing, $1.5bn Buyback Shift and Fresh Fund Moves – 17 November 2025 Update

Light & Wonder, Inc. (ASX: LNW, formerly NASDAQ: LNW) has hit a turning point this week. As of 17 November 2025, the cross‑platform gaming group has fully completed its move to a sole listing on the Australian Securities Exchange (ASX), shifted its US$1.5 billion share buyback onto the Australian market, and attracted fresh attention from both institutional investors and brokers. AGB Today’s key Light & Wonder headlines (17 November 2025) ASX‑only listing now in effect Light & Wonder has spent months preparing to exit Nasdaq and concentrate trading on the ASX. The company first notified Nasdaq of its intention to
17 November 2025
·
Beyond Meat (BYND) Stock News Today, November 17, 2025: Class Action Probe, Meme-Stock Hangover and Heavy Dilution Risks

Beyond Meat (BYND) Stock News Today, November 17, 2025: Class Action Probe, Meme-Stock Hangover and Heavy Dilution Risks

Beyond Meat, Inc. (NASDAQ: BYND) is back in the spotlight today as fresh legal scrutiny, shifting short interest, and lingering questions about its debt restructuring collide with a battered share price hovering just above the $1 mark. As of today, Beyond Meat stock is trading around $1.08, giving the plant-based meat maker a market cap of roughly $490 million, a dramatic comedown from its 2019 IPO glory days. Google+2 1. New Securities-Fraud Investigation Announced This Morning The headline news for November 17, 2025 is a fresh securities-fraud class action investigation into Beyond Meat by law firm Bleichmar Fonti & Auld
17 November 2025
Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) moved sharply higher today after the company confirmed that TONMYA™ (cyclobenzaprine HCl sublingual tablets), its newly approved fibromyalgia treatment, is now commercially available by prescription across the United States.GlobeNewswire+1 TONMYA Officially Launches in the U.S. Tonix announced at 7:00 a.m. EST that TONMYA is available for pharmacy ordering nationwide and can now be prescribed for adults with fibromyalgia.GlobeNewswire The drug is: TONMYA became the first new FDA‑approved therapy for fibromyalgia in more than 15 years when regulators cleared it on August 15, 2025, based on two pivotal Phase 3 trials involving nearly 1,000 patients.Tonix
17 November 2025
·
Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

As of this afternoon, Galmed Pharmaceuticals shares were changing hands around $1.18, up roughly 13% on the day, with more than 41 million shares traded—massively above the stock’s usual daily volume. TipRanks What Galmed Announced Today From its headquarters in Ramat Gan, Israel, Galmed Pharmaceuticals Ltd. announced fresh results from its ongoing collaboration with Virginia Commonwealth University (VCU) on overcoming drug resistance in GI cancers. Galmed Pharmaceuticals+1 The headline: A three‑drug combination of Aramchol + Stivarga + metformin produced a synergistic anti‑tumor effect, significantly enhancing GI tumor cell killing both in vitro and in vivo. According to today’s press release
17 November 2025
···
Autonomix Medical (AMIX) Stock Doubles on New Pancreatic Cancer Quality‑of‑Life Data – November 17, 2025 Update

Autonomix Medical (AMIX) Stock Doubles on New Pancreatic Cancer Quality‑of‑Life Data – November 17, 2025 Update

All of today’s Autonomix (AMIX) news in one glance – 17 November 2025 As of this afternoon on November 17, 2025, all company‑specific news about Autonomix Medical, Inc. (NASDAQ: AMIX) centers on the same core development: new quality‑of‑life data from its pancreatic cancer PoC 1 study and the stock’s reaction to it. The main headlines are: No additional Autonomix‑specific earnings reports, SEC filings or separate product announcements have been released today beyond coverage of this PoC 1 subgroup analysis and its market impact, based on public news and filings available at the time of writing. Last10K+1 What Autonomix announced today
17 November 2025
·
Michael Saylor’s Strategy Bets $835M on the Bitcoin Dip as Crypto Market Slides Below $95K

Michael Saylor’s Strategy Bets $835M on the Bitcoin Dip as Crypto Market Slides Below $95K

Bitcoin may be stuck in its deepest correction of 2025, but Michael Saylor is leaning in, not backing out. Over the past week, Strategy Inc. (MSTR) — the enterprise software company turned Bitcoin mega‑holder led by executive chairman Michael Saylor — acquired 8,178 BTC for about $835.6 million, its largest weekly buy since July.Bloomberg+1 At the same time, Saylor has a clear message for nervous investors watching Bitcoin bleed: HODL. Key facts at a glance Strategy’s Biggest Bitcoin Buy Since July According to a Monday filing with the U.S. Securities and Exchange Commission, Strategy disclosed that it had bought $835.6
17 November 2025
·
MSP Recovery (MSPR) Stock Jumps Over 20% Pre‑Market as Q3 Delay and Nasdaq Fight Keep Volatility High – 17 November 2025

MSP Recovery (MSPR) Stock Jumps Over 20% Pre‑Market as Q3 Delay and Nasdaq Fight Keep Volatility High – 17 November 2025

Important: This article is news and analysis, not investment advice. MSPR is a highly speculative micro‑cap; anyone considering it should do independent research and consider professional guidance. What’s Happening With MSPR Today (17 November 2025)? Pre‑market spike puts MSPR back on trader radars In the very early hours of Monday’s U.S. session, Benzinga’s pre‑market movers roundup flagged MSP Recovery as one of the most aggressive gainers in the market. At about 4:42 a.m. ET, the outlet reported MSPR up 38.6% to $0.6230 in pre‑market trading, noting that the stock had fallen roughly 5% on Friday. A few hours later, Benzinga’s
17 November 2025
··
Saab AB (SAAB-B.ST) Jumps on €3.1bn Gripen Colombia Deal as New Drone and Solar Partnerships Emerge – 17 November 2025

Saab AB (SAAB-B.ST) Jumps on €3.1bn Gripen Colombia Deal as New Drone and Solar Partnerships Emerge – 17 November 2025

Swedish defence and security group Saab AB (publ) (B‑share ticker SAAB‑B.ST) is firmly in the spotlight today after a wave of fighter‑jet contracts, electronic‑warfare orders and new technology partnerships pushed the stock sharply higher and sparked fresh debate about valuation and future growth. By mid‑afternoon on Monday, Saab’s B‑share was trading around SEK 555, up roughly 5–6% on the day and near its 52‑week high, leaving the OMXS30 benchmark in the dust. Year‑to‑date, the share has gained more than 120%, according to Saab’s own investor data and market feeds. Start+2MarketScreener+2 Below is a full rundown of the key Saab developments
17 November 2025
···
Sigma Lithium (SGML) Stock Soars in Premarket as Lithium Demand Hopes Collide With Q3 2025 Turnaround

Sigma Lithium (SGML) Stock Soars in Premarket as Lithium Demand Hopes Collide With Q3 2025 Turnaround

Sigma Lithium Corporation (NASDAQ: SGML, TSXV: SGML) is back on traders’ radar this Monday, with the stock ripping higher in premarket trading as investors react to a powerful mix of macro lithium news, fresh institutional buying and the company’s latest Q3 2025 results. SGML Stock Jumps More Than 30% in Premarket Trade Sigma Lithium is one of today’s standout premarket gainers in the U.S. market. These sharp moves come after SGML closed last session at $6.06 (Friday), already up about 2.7% on heavy volume of 8.29 million shares—more than double its recent average of 3.85 million. MarketBeat+1 In other words:
17 November 2025
···
Backbone Pro Xbox Edition: Price, Features, Release Date and Why It’s the New Go‑To Controller for Xbox Cloud Gaming (November 17, 2025)

Backbone Pro Xbox Edition: Price, Features, Release Date and Why It’s the New Go‑To Controller for Xbox Cloud Gaming (November 17, 2025)

Backbone Pro Xbox Edition is the latest “Designed for Xbox” mobile controller, blending full-size gamepad comfort with cross‑device Xbox Cloud Gaming support. Here’s everything you need to know today, November 17, 2025 – price, specs, compatibility, and early reactions. What is the Backbone Pro – Xbox Edition? Backbone’s new Pro – Xbox Edition is a premium, officially licensed Xbox controller designed to follow you from your phone to your TV, PC, tablet, laptop, and even VR headsets. It’s essentially a “console-grade” pad that can snap around your smartphone or work as a standalone wireless controller. Microsoft and Backbone first detailed
17 November 2025
Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is in the spotlight today after announcing positive Phase 3 data for its cancer drug Ziihera® (zanidatamab‑hrii) in a large global trial for HER2‑positive gastroesophageal adenocarcinoma (GEA). The news has triggered sharp pre‑market moves in Jazz’s share price and its partners’ stocks, and could reshape the treatment landscape for a difficult‑to‑treat cancer. PR Newswire+1 JAZZ stock today: volatility after a major cancer win As of early afternoon U.S. trading on Monday, November 17, Jazz Pharmaceuticals shares are trading around $141.07, little changed on the day according to real‑time quote data. Earlier, however, markets reacted far
17 November 2025
·
Dragonfly Energy (DFLI) Stock Pops as Canaccord Hikes Price Target to $2.25 After Big Q3 Earnings Beat

Dragonfly Energy (DFLI) Stock Pops as Canaccord Hikes Price Target to $2.25 After Big Q3 Earnings Beat

Dragonfly Energy Holdings Corp. (NASDAQ: DFLI), the lithium battery technology company behind the Battle Born® brand, is back in the spotlight today after a powerful combination of an earnings surprise, an aggressive analyst upgrade and a sweeping balance sheet reset. Canaccord Genuity this morning more than doubled its 12‑month price target on Dragonfly Energy from $1.00 to $2.25 while reiterating a Buy rating, implying roughly 178% upside from around $0.81 per share.Investing.com The call lands just days after Dragonfly’s Q3 2025 results showed strong OEM growth, sharply higher gross margins and progress on debt reduction. In Monday trading, DFLI was
17 November 2025
··
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far.Reuters+1 The move deepens J&J’s bet on cancer medicines just as sales of its long‑time blockbuster psoriasis drug Stelara are being hit hard by a wave of cheaper biosimilar rivals.Yahoo Finance+1 Key points Inside Johnson & Johnson’s Halda Therapeutics takeover J&J said on Monday that it will acquire Halda Therapeutics for $3.05 billion in cash, adding a new set of precision oncology assets to its Innovative Medicine unit.Reuters+1
17 November 2025
··
Interstellar Comet 3I/ATLAS: ESA Sharpens Its Path as December Flyby Fuels Livestreams and Debunks Doomsday Rumors

Interstellar Comet 3I/ATLAS: ESA Sharpens Its Path as December Flyby Fuels Livestreams and Debunks Doomsday Rumors

Interstellar comet 3I/ATLAS (C/2025 N1 ATLAS) – a frozen wanderer from another star system – is back in the news today as space agencies and observatories around the world fine‑tune its trajectory, release new images and prepare global livestreams ahead of its safe flyby of Earth in December 2025. At the same time, scientists are working hard to knock down viral claims that the comet is either an alien spacecraft or on a collision course with our planet. Spoiler: it’s neither. Here’s what you need to know today. What is 3I/ATLAS – and why is it such a big deal?
17 November 2025
Twin Vee PowerCats (VEEE) Stock Jumps in Premarket as Bahama Boats Roll Out: Latest News for 17 November 2025

Twin Vee PowerCats (VEEE) Stock Jumps in Premarket as Bahama Boats Roll Out: Latest News for 17 November 2025

On Monday morning, 17 November 2025, micro‑cap boat builder Twin Vee PowerCats Co. (NASDAQ: VEEE) popped up on traders’ screens as one of the day’s more volatile pre‑market movers. Multiple market outlets flagged the stock after it surged roughly 15–22% in early trading, hovering around the $2.00 level, before regular‑session trading pulled the price back toward the mid‑$1 range later in the day. Benzinga+1 The move comes just days after Twin Vee announced the start of customer deliveries for its newly acquired Bahama Boat Works brand and reported third‑quarter results that showed narrowing losses but continued cash burn. Twin Vee
17 November 2025
WeShop Holdings (NASDAQ: WSHP) Soars Again as Nasdaq Composite Adds New Social‑Commerce Stock – 17 November 2025 Update

WeShop Holdings (NASDAQ: WSHP) Soars Again as Nasdaq Composite Adds New Social‑Commerce Stock – 17 November 2025 Update

WeShop Holdings Limited’s Class A Ordinary Shares (NASDAQ: WSHP) are back in the spotlight today, 17 November 2025, as the newly listed social‑commerce stock rips higher in pre‑market trading and is added to the Nasdaq Composite Index just days after its debut. Below is a full rundown of everything that happened today around WSHP, and what it could mean for investors watching this fast‑moving name. WSHP Stock Today: Pre‑Market Moves Near +90–100% WeShop’s first regular trading session on Friday, 14 November, ended with the stock at $30.21, up 91.99% from its reference price, after trading between $20.02 and $39.22 during
17 November 2025
·
1 … 22 23 24 25 26 … 140

Stock Market Today

Nu stock jumps to $17.40 as traders eye Nubank’s next catalyst

Nu stock jumps to $17.40 as traders eye Nubank’s next catalyst

7 February 2026
Nu Holdings shares climbed 3.5% to $17.40 Friday, reversing Thursday’s loss, as the Dow closed above 50,000 for the first time. Nu recently received conditional approval from U.S. regulators to form a national bank, but still needs further sign-offs before launching. The company manages $38.8 billion in deposits and reports earnings Feb. 25.
MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Go toTop